1-4 of 4
Ewa Stefanska-Windyga
Close
Sort by
Journal Articles

Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor - Real-World Evidence from Poland

Jerzy Windyga, Joanna Zdziarska, Ewa Stefanska-Windyga, Ewa Chmielewska, Krzysztof Chojnowski, Michal Jamrozik, Aleksandra Kostyra, Justyna Kozinska, Halyna Krainiak, Jolanta Oleksiuk, Joanna Rupa-Matysek, Ewa Zarzycka, Anna Buczma
Journal: Blood
Blood (2022) 140 (Supplement 1): 5621–5622.
https://doi.org/10.1182/blood-2022-163567
Published: 2022
Journal Articles

Personalization of Clotting Factor VIII Replacement Therapy Based on Population Pharmacokinetics in Adult Patients with Severe Hemophilia a Who Frequently Switch Factor VIII Concentrates

Jerzy Windyga, Edyta Odnoczko, Ewa Stefanska-Windyga, Beata Baran, Anna Sikorska, Magdalena Gorska-Kosicka, Janusz Zawilski, Magdalena Letowska
Journal: Blood
Blood (2022) 140 (Supplement 1): 8451–8452.
https://doi.org/10.1182/blood-2022-164998
Published: 2022
Journal Articles

The Influence of Personalized 2-Year Physiotherapy on Musculoskeletal Health and Quality of Life in Severe Hemophilia Patients with Inhibitor - Interim Analysis after 1 Year of the Program

Maria Helena Podolak-Dawidziak, professor, Janusz Zawilski, Mariola Bober, Ewa Stefanska-Windyga, MDPhD, Anna Buczma, MD, Iwona Prajs, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36.
https://doi.org/10.1182/blood-2020-139151
Published: 2020
Journal Articles

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Magdalena Katarzyna Letowska, Krystyna Zawilska, MD PhD, Anna Klukowska, MD PhD, Krzysztof Chojnowski, MD PhD, Joanna Zdziarska, MD PhD, Ewa Stefanska-Windyga, MD PhD, Jerzy Windyga
Journal: Blood
Blood (2019) 134 (Supplement_1): 4942.
https://doi.org/10.1182/blood-2019-122422
Published: 2019